Literature DB >> 15648271

Effects of hydrophilic cyclodextrins on aggregation of recombinant human growth hormone.

Sumitra Tavornvipas1, Shinichiro Tajiri, Fumitoshi Hirayama, Hidetoshi Arima, Kaneto Uekama.   

Abstract

PURPOSE: To evaluate the effect of hydrophilic cyclodextrins (CyDs) on the aggregation induced by different stresses and on the oxidation and deamidation of recombinant human growth hormone (rhGH).
METHODS: The aggregation of rhGH was induced by three denaturing techniques including chemical (4.5 M guanidine hydrochloride), thermal (differential scanning calorimetry), and interfacial denaturation (vortex agitation). The aggregates were characterized and quantified by UV spectrophotometry and size exclusion chromatography. The effects of hydrophilic CyDs on deamidation and oxidation rates of rhGH were studied by HPLC method.
RESULTS: In both thermally and chemically induced aggregations, branched beta-CyDs significantly inhibited the aggregation of rhGH compared with the other alpha- and gamma-CyDs. This can explain that the beta-CyD cavity with branched sugar moieties may be relatively preferable in preventing the aggregation of rhGH. In contrast, 2-hydroxypropyl beta-CyD with surface activity was found to be effective in reducing the aggregation induced by interfacial denaturation compared with those of branched beta-CyDs. On the other hand, these hydrophilic CyDs showed no noticeable inhibitory effect on the oxidation and deamidation rates of rhGH. The results suggested that CyDs interact preferably with exposed hydrophobic side chains rather than aliphatic side chains of rhGH, resulting in the inhibition of aggregation but not the oxidation and deamidation rates.
CONCLUSIONS: The different inhibitory effect of CyDs is dependent not only on the structure and property of CyD itself but also the nature of the denaturing stimulus. The current results suggested that hydrophilic beta-CyDs can effectively inhibit the aggregation of rhGH. Thus, hydrophilic beta-CyDs may be potentially useful excipients for parenteral preparation of rhGH.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15648271     DOI: 10.1007/s11095-004-7691-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  22 in total

1.  Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-03-01       Impact factor: 15.470

Review 2.  Protein folding and misfolding.

Authors:  Christopher M Dobson
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

3.  The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) (PLGA) microspheres.

Authors:  J L Cleland; A Mac; B Boyd; J Yang; E T Duenas; D Yeung; D Brooks; C Hsu; H Chu; V Mukku; A J Jones
Journal:  Pharm Res       Date:  1997-04       Impact factor: 4.200

Review 4.  The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation.

Authors:  J L Cleland; M F Powell; S J Shire
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1993       Impact factor: 4.889

5.  Stabilization of protein structure by sugars.

Authors:  T Arakawa; S N Timasheff
Journal:  Biochemistry       Date:  1982-12-07       Impact factor: 3.162

6.  Use of 2-hydroxypropyl-beta-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs.

Authors:  M E Brewster; M S Hora; J W Simpkins; N Bodor
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

7.  Molten globule intermediate of recombinant human growth hormone: stabilization with surfactants.

Authors:  N B Bam; J L Cleland; T W Randolph
Journal:  Biotechnol Prog       Date:  1996 Nov-Dec

8.  Protection afforded by maltosyl-beta-cyclodextrin against alpha-chymotrypsin-catalyzed hydrolysis of a luteinizing hormone-releasing hormone agonist, buserelin acetate.

Authors:  K Matsubara; Y Ando; T Irie; K Uekama
Journal:  Pharm Res       Date:  1997-10       Impact factor: 4.200

9.  Varying effects of cyclodextrin derivatives on aggregation and thermal behavior of insulin in aqueous solution.

Authors:  K Tokihiro; T Irie; K Uekama
Journal:  Chem Pharm Bull (Tokyo)       Date:  1997-03       Impact factor: 1.645

10.  Thermodynamic characterization of an intermediate state of human growth hormone.

Authors:  I Gomez-Orellana; B Variano; J Miura-Fraboni; S Milstein; D R Paton
Journal:  Protein Sci       Date:  1998-06       Impact factor: 6.725

View more
  10 in total

1.  Assisting the reactivation of guanidine hydrochloride-denatured aminoacylase by hydroxypropyl cyclodextrins.

Authors:  Sung-Hye Kim; Jun Zhang; Yan Jiang; Hai-Meng Zhou; Yong-Bin Yan
Journal:  Biophys J       Date:  2006-04-21       Impact factor: 4.033

2.  Antichaperone activity of cyclodextrin derivatives.

Authors:  O I Maloletkina; K A Markosyan; R A Asriyants; V N Orlov; B I Kurganov
Journal:  Dokl Biochem Biophys       Date:  2009 Jul-Aug       Impact factor: 0.788

Review 3.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

4.  The role of polysorbate 80 and HPβCD at the air-water interface of IgG solutions.

Authors:  Tim Serno; Elisabeth Härtl; Ahmed Besheer; Reinhard Miller; Gerhard Winter
Journal:  Pharm Res       Date:  2012-08-22       Impact factor: 4.200

5.  Determining the Binding Sites of β-Cyclodextrin and Peptides by Electron-Capture Dissociation High Resolution Tandem Mass Spectrometry.

Authors:  Yulin Qi; Timon Geib; Dietrich A Volmer
Journal:  J Am Soc Mass Spectrom       Date:  2015-04-11       Impact factor: 3.109

6.  Cyclodextrin/chitosan nanoparticles for oral ovalbumin delivery: Preparation, characterization and intestinal mucosal immunity in mice.

Authors:  Muye He; Chen Zhong; Huibing Hu; Yu Jin; Yanzuo Chen; Kaiyan Lou; Feng Gao
Journal:  Asian J Pharm Sci       Date:  2018-09-01       Impact factor: 6.598

7.  Transdermal Co-Delivery of Urea and Recombinant Human Growth Hormone.

Authors:  Leila Shams; Mahvash Khodabandeh Shahraky; Mona Sadat Mirtaleb
Journal:  Iran J Biotechnol       Date:  2021-10-01       Impact factor: 1.671

8.  Polysorbates versus Hydroxypropyl Beta-Cyclodextrin (HPβCD): Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies.

Authors:  Hailong Zhang; Shiqi Hong; Sarah Si Kai Tan; Tao Peng; Lucas Yuan Hao Goh; Kwan Hang Lam; Keat Theng Chow; Rajeev Gokhale
Journal:  Molecules       Date:  2022-10-01       Impact factor: 4.927

9.  Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study.

Authors:  Suzan M Mansour; Rehab N Shamma; Kawkab A Ahmed; Nirmeen A Sabry; Gamal Esmat; Azza A Mahmoud; Amr Maged
Journal:  Int Immunopharmacol       Date:  2021-07-23       Impact factor: 4.932

10.  The Role of Cyclodextrins against Interface-Induced Denaturation in Pharmaceutical Formulations: A Molecular Dynamics Approach.

Authors:  Marcello Rospiccio; Andrea Arsiccio; Gerhard Winter; Roberto Pisano
Journal:  Mol Pharm       Date:  2021-05-17       Impact factor: 4.939

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.